Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 19.07
NONOF's Cash to Debt is ranked lower than
53% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. NONOF: 19.07 )
Ranked among companies with meaningful Cash to Debt only.
NONOF' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 2.85 Max: 67.3
Current: 19.07
0.29
67.3
Equity to Asset 0.51
NONOF's Equity to Asset is ranked lower than
70% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NONOF: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
NONOF' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.66 Max: 0.73
Current: 0.51
0.51
0.73
Interest Coverage 284.18
NONOF's Interest Coverage is ranked lower than
59% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NONOF: 284.18 )
Ranked among companies with meaningful Interest Coverage only.
NONOF' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 40.73 Max: 884.41
Current: 284.18
9.18
884.41
F-Score: 8
Z-Score: 16.27
M-Score: -2.20
WACC vs ROIC
12.18%
142.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating margin (%) 43.61
NONOF's Operating margin (%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. NONOF: 43.61 )
Ranked among companies with meaningful Operating margin (%) only.
NONOF' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 32.40 Max: 45.81
Current: 43.61
21.38
45.81
Net-margin (%) 32.30
NONOF's Net-margin (%) is ranked higher than
92% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. NONOF: 32.30 )
Ranked among companies with meaningful Net-margin (%) only.
NONOF' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 24.74 Max: 32.3
Current: 32.3
16.65
32.3
ROE (%) 86.46
NONOF's ROE (%) is ranked higher than
98% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. NONOF: 86.46 )
Ranked among companies with meaningful ROE (%) only.
NONOF' s ROE (%) Range Over the Past 10 Years
Min: 22.36  Med: 42.79 Max: 79.9
Current: 86.46
22.36
79.9
ROA (%) 42.22
NONOF's ROA (%) is ranked higher than
98% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. NONOF: 42.22 )
Ranked among companies with meaningful ROA (%) only.
NONOF' s ROA (%) Range Over the Past 10 Years
Min: 14.9  Med: 25.96 Max: 41.29
Current: 42.22
14.9
41.29
ROC (Joel Greenblatt) (%) 181.83
NONOF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. NONOF: 181.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NONOF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.68  Med: 87.94 Max: 178.92
Current: 181.83
36.68
178.92
Revenue Growth (3Y)(%) 14.00
NONOF's Revenue Growth (3Y)(%) is ranked higher than
66% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NONOF: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NONOF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.3  Med: 14.00 Max: 127.9
Current: 14
-46.3
127.9
EBITDA Growth (3Y)(%) 17.60
NONOF's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. NONOF: 17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NONOF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.4  Med: 16.70 Max: 130.3
Current: 17.6
-44.4
130.3
EPS Growth (3Y)(%) 20.30
NONOF's EPS Growth (3Y)(%) is ranked higher than
76% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NONOF: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NONOF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.6  Med: 20.40 Max: 36.9
Current: 20.3
5.6
36.9
» NONOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.53
NONOF's P/E(ttm) is ranked higher than
57% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. NONOF: 26.53 )
Ranked among companies with meaningful P/E(ttm) only.
NONOF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 24.04 Max: 35.76
Current: 26.53
12.13
35.76
Forward P/E 20.79
NONOF's Forward P/E is ranked lower than
58% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. NONOF: 20.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.53
NONOF's PE(NRI) is ranked higher than
57% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. NONOF: 26.53 )
Ranked among companies with meaningful PE(NRI) only.
NONOF' s PE(NRI) Range Over the Past 10 Years
Min: 12.03  Med: 24.03 Max: 35.76
Current: 26.53
12.03
35.76
Price/Owner Earnings (ttm) 28.60
NONOF's Price/Owner Earnings (ttm) is ranked higher than
59% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. NONOF: 28.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NONOF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 29.40 Max: 68.66
Current: 28.6
13.81
68.66
P/B 19.86
NONOF's P/B is ranked lower than
93% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. NONOF: 19.86 )
Ranked among companies with meaningful P/B only.
NONOF' s P/B Range Over the Past 10 Years
Min: 3.66  Med: 7.78 Max: 31.9
Current: 19.86
3.66
31.9
P/S 8.59
NONOF's P/S is ranked higher than
57% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. NONOF: 8.59 )
Ranked among companies with meaningful P/S only.
NONOF' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.82 Max: 11.01
Current: 8.59
2.8
11.01
PFCF 29.03
NONOF's PFCF is ranked higher than
53% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. NONOF: 29.03 )
Ranked among companies with meaningful PFCF only.
NONOF' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.36 Max: 47.08
Current: 29.03
12.07
47.08
POCF 24.18
NONOF's POCF is ranked higher than
51% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. NONOF: 24.18 )
Ranked among companies with meaningful POCF only.
NONOF' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.36 Max: 32.54
Current: 24.18
9.91
32.54
EV-to-EBIT 20.97
NONOF's EV-to-EBIT is ranked higher than
55% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. NONOF: 20.97 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.90 Max: 25.7
Current: 20.97
9.2
25.7
EV-to-EBITDA 19.63
NONOF's EV-to-EBITDA is ranked higher than
52% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. NONOF: 19.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
NONOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.40 Max: 25.1
Current: 19.63
8.2
25.1
PEG 1.50
NONOF's PEG is ranked higher than
63% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. NONOF: 1.50 )
Ranked among companies with meaningful PEG only.
NONOF' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.24 Max: 5.17
Current: 1.5
0.48
5.17
Shiller P/E 54.00
NONOF's Shiller P/E is ranked lower than
51% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. NONOF: 54.00 )
Ranked among companies with meaningful Shiller P/E only.
NONOF' s Shiller P/E Range Over the Past 10 Years
Min: 22.8  Med: 42.58 Max: 67.58
Current: 54
22.8
67.58
Current Ratio 1.35
NONOF's Current Ratio is ranked lower than
85% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NONOF: 1.35 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.23 Max: 2.45
Current: 1.35
1.35
2.45
Quick Ratio 1.04
NONOF's Quick Ratio is ranked lower than
86% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. NONOF: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.45 Max: 1.91
Current: 1.04
1.04
1.91
Days Inventory 279.54
NONOF's Days Inventory is ranked lower than
83% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. NONOF: 279.54 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 292.48 Max: 343.56
Current: 279.54
246.45
343.56
Days Sales Outstanding 52.37
NONOF's Days Sales Outstanding is ranked higher than
60% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. NONOF: 52.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 52.37
45.09
53.6
Days Payable 111.09
NONOF's Days Payable is ranked higher than
68% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. NONOF: 111.09 )
Ranked among companies with meaningful Days Payable only.
NONOF' s Days Payable Range Over the Past 10 Years
Min: 65.17  Med: 93.12 Max: 124.07
Current: 111.09
65.17
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.76
NONOF's Dividend Yield is ranked higher than
68% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. NONOF: 1.76 )
Ranked among companies with meaningful Dividend Yield only.
NONOF' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 1.51 Max: 2.47
Current: 1.76
0.79
2.47
Dividend Payout 0.37
NONOF's Dividend Payout is ranked lower than
59% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. NONOF: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
NONOF' s Dividend Payout Range Over the Past 10 Years
Min: 0.13  Med: 0.27 Max: 0.45
Current: 0.37
0.13
0.45
Dividend Growth (3y) 21.30
NONOF's Dividend Growth (3y) is ranked higher than
80% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. NONOF: 21.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NONOF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 22.70 Max: 49.4
Current: 21.3
0
49.4
Forward Dividend Yield 1.76
NONOF's Forward Dividend Yield is ranked higher than
66% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. NONOF: 1.76 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 8.87
NONOF's Yield on cost (5-Year) is ranked higher than
96% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. NONOF: 8.87 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NONOF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.98  Med: 7.61 Max: 12.45
Current: 8.87
3.98
12.45
3-Year Average Share Buyback Ratio 2.20
NONOF's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NONOF: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NONOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.3  Med: 2.20 Max: 49.1
Current: 2.2
-92.3
49.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 89.70
NONOF's Price/Net Current Asset Value is ranked lower than
97% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. NONOF: 89.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NONOF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 23.76 Max: 100.73
Current: 89.7
11.62
100.73
Price/Tangible Book 20.81
NONOF's Price/Tangible Book is ranked lower than
90% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. NONOF: 20.81 )
Ranked among companies with meaningful Price/Tangible Book only.
NONOF' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 5.90 Max: 23.2
Current: 20.81
3.14
23.2
Price/Projected FCF 3.70
NONOF's Price/Projected FCF is ranked lower than
52% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. NONOF: 3.70 )
Ranked among companies with meaningful Price/Projected FCF only.
NONOF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.96 Max: 7.38
Current: 3.7
1.45
7.38
Price/DCF (Earnings Based) 0.93
NONOF's Price/DCF (Earnings Based) is ranked higher than
61% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. NONOF: 0.93 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.48
NONOF's Price/Median PS Value is ranked lower than
75% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. NONOF: 1.48 )
Ranked among companies with meaningful Price/Median PS Value only.
NONOF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.88 Max: 1.65
Current: 1.48
0.5
1.65
Price/Peter Lynch Fair Value 1.06
NONOF's Price/Peter Lynch Fair Value is ranked higher than
75% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. NONOF: 1.06 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NONOF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.27  Med: 1.13 Max: 3.78
Current: 1.06
0.27
3.78
Price/Graham Number 4.95
NONOF's Price/Graham Number is ranked lower than
77% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. NONOF: 4.95 )
Ranked among companies with meaningful Price/Graham Number only.
NONOF' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 2.76 Max: 5.52
Current: 4.95
1.56
5.52
Earnings Yield (Greenblatt) (%) 4.76
NONOF's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. NONOF: 4.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NONOF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.90 Max: 10.8
Current: 4.76
3.9
10.8
Forward Rate of Return (Yacktman) (%) 28.21
NONOF's Forward Rate of Return (Yacktman) (%) is ranked higher than
72% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. NONOF: 28.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NONOF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 23.20 Max: 38.6
Current: 28.21
7.5
38.6

More Statistics

Revenue(Mil) $16279
EPS $ 2.04
Beta0.56
Short Percentage of Float0.00%
52-Week Range $46.42 - 59.90
Shares Outstanding(Mil)2600.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 19,767 20,730 22,222
EPS($) 2.62 2.90 3.14
EPS without NRI($) 2.62 2.90 3.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NVO.USA,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
Value Investing in BioPharma Nov 18 2015 
Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 

More From Other Websites
How Has Novo’s Share Price Performed since Its Last Earnings? May 02 2016
Novo Impressed Wall Street with Its 1Q16 Earnings May 02 2016
Novo Nordisk (NVO) Beats on Q1 Earnings, Retains Outlook May 02 2016
5 Large-Cap Stocks to Buy as the S&P Makes New Highs Apr 21 2016
How Much Potential Does Saxenda Hold for Novo? Apr 17 2016
Long views, deep pockets: Danish foundations keep pharma groups healthy Apr 17 2016
Long views, deep pockets: Danish foundations keep pharma groups healthy Apr 16 2016
Victoza to Fuel Growth for Novo Nordisk Apr 15 2016
Analyzing Novo’s Haemophilia and Growth Hormone Portfolio Apr 13 2016
How Is Novo Nordisk Doing in the Diabetes Space? Apr 12 2016
Why Did Novo’s Share Price Fall after Fiscal 2015 Earnings? Mar 31 2016
What Is Novo’s Price-to-Earnings Valuation? Mar 31 2016
Novo Nordisk gives hiring update on 700 jobs pledge, breaks ground on Clayton facility Mar 28 2016
America's Best Midsize Employers 2016 Mar 23 2016
China’s diabetes boom promises $23 billion pot for drug makers Mar 21 2016
Novo Nordisk Is A Best Idea Mar 18 2016
Oil prices should be more comfortable: Novo Nordisk Mar 15 2016
Novo Nordisk Victoza Lowers Cardiovascular Risk Per Study Mar 07 2016
Novo Nordisk Pops As Diabetes Drug Cuts Heart Disease Deaths Mar 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK